Impacting Emergency Department Bleeds: The Change is Here and Now
/
W. Brian Gibler, MD
President, EMCREG-International
Professor of Emergency Medicine
Department of Emergency Medicine
University of Cincinnati College of Medicine
Cincinnati, OH
Gregory J. Fermann, MD
Professor of Emergency Medicine
Department of Emergency Medicine
University of Cincinnati College of Medicine
Cincinnati, OH
The development of direct oral anticoagulants (DOACs), such as dabigatran, betrixaban, rivaroxaban, apixaban, and edoxaban, represent an important advance in anticoagulation therapy. Antidotes that can neutralize the effect of DOACs have been in development for several years, and approvals have been granted over the last couple. While data are available with these reversal agents in patients requiring urgent procedures, they still are fairly recent. As such, the mechanisms of action, and consequently the likelihood of benefit, are not broadly known by clinicians. Managing the vast array of patients admitted to the emergency department (ED) is challenging, especially with regard to how to triage patients appropriately on anticoagulation therapy with breakthrough bleeding.
Expert faculty from the University of Cincinnati College of Medicine in collaboration with MedEd On The Go review major and minor bleeds, key considerations and recommendations associated with reversal agents for DOACs, and employing swift treatment strategies within the emergency department.
AGENDA
Indications for Anticoagulation
Agents for Anticoagulation
Severe Bleeding in the ED or ICU for Anticoagulated Patients
Uniform Approach to Treatment Regardless of Anticoagulant Bleeds with Vitamin K Antagonist Managed in the ED or ICU
Bleeds with Dabigatran Managed in the ED or ICU
Bleeds with Factor Xa Inhibitors Managed in the ED or ICU
Continuum of Care in a Hemorrhaging Patient
Impacting Emergency Department Bleeds: The Change is Here and Now - Program Summary